Atlantis, Evan http://orcid.org/0000-0001-5877-6141
Kormas, Nic
Piya, Milan
Sahebol-Amri, Mehdi
Williams, Kathryn
Huang, Hsin-Chia Carol
Bishay, Ramy
Chikani, Viral
Girolamo, Teresa
Prodan, Ante
Fahey, Paul
Funding for this research was provided by:
Western Sydney University
Article History
Received: 5 October 2023
Revised: 20 February 2024
Accepted: 22 February 2024
First Online: 11 March 2024
Declarations
:
: The study protocol was approved by the South Western Sydney Local Health District Research and Ethics Office (Ref: 2019/ETH13608) and recognized by the Western Sydney university Human Research Ethics Committee (Ethics Reference: RH13705).
: In this study, we analyzed retrospective de-identified medical records of patients who were no longer receiving active treatments. We obtained a waiver of consent for this study in accordance with the National Statement on Ethical Conduct in Human Research (2007). The records were kept confidential and private throughout the study. For this type of study, formal consent is not required.
: This pilot work was supported by grants from Novo Nordisk Pharmaceuticals, in partnership with the National Association of Clinical Obesity Services (NACOS) and Western Sydney University (P00026163). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the abstract. EA is the Founding President of NACOS and is employed at Western Sydney University. He has also received honoraria from Novo Nordisk and NACOS for participating at conferences. KW has received honoraria from Novo Nordisk, Eli Lilly, Pfizer, and Boehringer Ingelheim. TG has received honoraria for educational events sponsored by Novo Nordisk, Inova Pharmaceuticals, and Johnson & Johnson and for serving on advisory boards for Novo Nordisk and Inova Pharmaceuticals. MS received financial support from the above grant (P00026163) as a project officer.